UK biotech KaNDy Therapeutics is heading to phase 3 with its non-hormonal menopause drug, after a mid-stage trial showed it reduced hot flashes as well as improved quality of life, setting
Two biotechs, Neurocrine Biosciences and Xenon, have announced a licence and collaboration agreement to develop first-in-class treatments for epilepsy in a deal worth up to $1.75 billion.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
